SYNTHESIS AND ANTICONVULSANT ACTIVITY OF SOME NEW 1, 6-DIPHENYL-10, 10a-
DIHYDROPYRIDO[2, 3-d]-1, 2, 4-TRIAZOLO [4, 3-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES

D.P. Kawade*1 and P.B. Khedekar 2

Priyadarshini J. L. College of Pharmacy 1, Electronic Zone Building, MIDC, Hingna Road, Nagpur-440 016, Maharashtra, India
Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University 2, Nagpur-440 033, Maharashtra, India

ABSTRACT: In this research, a new series of total twenty derivatives (39-58) of titled compound were synthesized with the help of substituted acetophenone which undergoes Aldol condensation reaction with dimethyformamidinedimethylacetal (DMFDMA) to form corresponding unsaturated carbonyl compounds such as enaminones. The compound 2-thioxo-1,3-dihydropyridino[2,3-d] pyrimidin-4(1H)-one were obtained by reacting enaminones with 6-amino-2-thioxo-2, 3-dihydropyrimidin-4(1H)-one in the presence of dioxane. In this reaction, 6-amino-2-thioxo-2, 3-dihydropyrimidin-4(1H)-one acts as a nucleophilic reagent. Thus, the titled compounds were obtained by cyclizing an intermediate followed by desulphuration with the liberation of hydrogen sulphide gas in the presence of acetic acid. The homogeneity and purity of synthesized compound was ascertained by physical constant determination and chromatographic methods. The structure of the synthesized derivative was further confirmed by spectral (FTIR, NMR, MS) and elemental (C, H, N) analysis. The anticonvulsant activity of the compounds (39-58) was evaluated against Maximal Electroshock (MES)-induced seizures. The compounds, those found effective, were as well tested against subcutaneous pentylenetetrazole (scPTZ)-induced seizures model in mice. Using the rotorod procedure, the neurotoxicity was assessed. The results of anticonvulsant activity (in vivo) indicated that the compounds (46) and (57) possessed significant activity when compared with Phenytoin as a standard.

INTRODUCTION: Pyrimidine is a heterocyclic compound in which the two nitrogen atoms are the heteroatom. A simple pyrimidine has been derived from benzene by the replacement of two of the ring carbon atoms by nitrogen. Pyrimidine (II), an isomeric diazine is single ring compound, with nitrogen in position one and three of a six membered benzene ring. Pyrimidine has been found to be associated with diverse biological activities and pyrimidine derivatives also play a key role in numerous biological processes 1-8.
Pyrimidine and purine bases are present in all nucleic acids \( Y = \text{H, OH} \). Nucleic acids are present in all living organisms, whether plants, animals or viruses, nucleic acids are the long chain heteropolymers made up of complex monomeric units called nucleotides. Each nucleotide is made up of one molecule of phosphoric acid, one molecule of pentose sugar and either a purine or a pyrimidine base (cytosine, uracil or thymine). There are two types of nucleic acids (IV), ribonucleic acid (RNA; \( Y = \text{OH} \)) and deoxyribonucleic acids (DNA; \( Y = \text{H} \)).

![Diagram of nucleotide structure](image)

The most common pyrimidines of DNA are cytosine (V), thymine (VI) and that of RNA are cytosine, uracil (VII).

![Pyrimidine structures](image)

The pyramidal nature of a few well-defined amino groups indicates that a strong correlation exists between the non-planarity of the amide and peptide torsion angles. The pyramidal nature of the amino groups might arise due to effect of lone pair of electrons at the central nitrogen atom. Amino groups are one of the various types of hydrogen bond donors, abundantly found in protein main-chain, side-chains and DNA bases. The design of pyrimidine antimetabolites has involved changes in the ring, isosteric replacement of ring atoms, changes in ring size, attached sugars and phosphate residues.

The most widely employed route to synthesize pyrimidine involves the combination of a reagent containing the N-C-N skeleton with C-C-C unit. These syntheses are typical examples of the bisnucleophile plus bis-electrophile method of constructing heterocycles. Both the nitrogen atom of the N-C-N reagent act as nucleophiles and both the terminal carbon atoms of C-C-C reagents are electrophiles. Urea, thiourea and guanidine are commonly used as N-C-N reagents and \( \beta \)-dialdehyde, \( \beta \)-ketoaldehyde and \( \beta \)-ketoester are typical C-C-C reagents (XIII-XI).

Out of above four routes, the condensation of the three-carbon unit to a species having N-C-N linkage is most widely used. The three-carbon unit may be

a) \( \beta \)-dialdehyde

b) \( \beta \)-ketoaldehyde

c) \( \beta \)-ketoester

d) \( \beta \)-ketonitrile or other combinations of these functional groups. The nitrogen containing unit may be urea, thiourea, amidine or guanidine.

**OBJECTIVE AND MECHANISM**

The compound 2-thioxo-1,3-dihydropyridin[2,3-d]pyrimidin-4 (1H)-one were obtained by reacting enamionones with 6-amino-2-thioxo-2, 3-dihydropyrimidin-4(1H)-one in glacial acetic acid. Following the above mentioned procedure, hydrazoloyl halides were reacted with triethylamine in the presence of chloroform to obtained tilted compound (39-58). The interesting CNS properties of several compounds with three angular fused heterocyclic systems are well known.
Antipsychotic activity of pyrazolopyrido-6(7H)-pyrimidinones and antidepressant effect of trizoloquinoxalines have been encouraged to synthesize pyrazolopyridopyrimidinone derivatives and further, shall be investigated for anticonvulsant activity.

Substituted acetophenone (XXXI) undergoes Aldol condensation reaction with dimethyformamidedimethylacetal (XXXII) to form corresponding enaminones, 3-(dimethylamino)-1-phenylprop-2-en-1-ones (XXXIII). The compound 2-thioxo-1,3-dihydropyrido[2,3-d] pyrimidin-4(1H)-one (XXXV) were obtained by reacting enamines (XXXIII) with 6-amino-2-thioxo-2, 3-dihydropyrimidin-4(1H)-one (XXXIV) in glacial acetic acid. In this reaction, 6-amino-2-thioxo-2, 3-dihydropyrimidin-4(1H)-one (XXXIV) acts as a nucleophilic reagent. The titled compounds (XXXVI) were obtained by cyclizing an intermediate followed by desulphuration with the liberation of hydrogen sulphide gas in the presence of acetic acid (FIG.1).

FIG. 1: REACTION MECHANISM OF 1,6-DIPHENYL-10,10a-DIHYDRO PYRIDO[2,3-d]-31,2,4TRIAZOLE[4,3-α] PYRIMIDIN-5(1H)-ONE DERIVATIVES
MATERIALS AND METHODS: The chemicals, solvents, drugs employed for synthetic work were of BDH/Hi-Media/E-Merck/Laboratory grade. The solvents were further purified by established methods. The starting material used in the synthesis was obtained from SD Fine. All the residues have been dried in vacuum desiccator and crystallized. The percentage yields are based upon the products obtained after purification through crystallization. The solvent used for crystallization has been mentioned within brackets after melting point. The melting points of the compounds were determined in open capillaries using Thermonik Precision Melting point apparatus (C-PMB-2, Mumbai) method and reported here-in are in the Celsius scale and are uncorrected. All the reactions were monitored by TLC performed on aluminium plates precoated with silica gel 60 (HF-254, E. Merck, India). The precoated plates were developed with iodine vapors after TLC. Solvent system (Chloroform: ethanol 3:1) was employed for thin layer chromatography and their Rf values has been reported in the preceding text.

The ultraviolet absorptions spectra were measured on Shimadzu 1601 spectrophotometer (methanol HPLC Grade). IR spectra were recorded on FTIR 8400s spectrophotometer (Kyoto, Japan) from Shimadzu using KBr optics (cm⁻¹) at Sharad Pawar College of Pharmacy, Nagpur. ¹H-NMR spectra were recorded on Varian EM 390 spectrophotometer (chemical shift in δ ppm), at Department of Chemistry, Pune University, Pune, using tetramethylsilane (TMS) as internal standard. The chemical shifts (δ) are reported in parts per million (ppm) relative to TMS in CDCl₃ solution. Signal multiplicities are presented by s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), bs (broad singlet) and m (multiplet). Mass spectra (EIMS) were recorded at 70 eV on JEOL D-300 spectrophotometer (Jeol Ltd., Tokyo, Japan). Elemental analysis were carried out using FLASH EA 1112 CHN analyzer (Thermo Finnigan, Italy) and found within limit of ± 0.4% of the theoretical values were taken into consideration.

SCHEME:

SYNTHESIS OF 1, 6-DIPHENYL-10,10a-DIHYDRO PYRIDO [2,3-d]-1,2,4-TRIAZOLO [4,3-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES (39-58)
Synthesis of 1,6-diphenyl-10,10a-dihydropyrido[2,3-d]-31,2,4-triazolo[4,3-a]pyrimidin-5(1H)-one derivatives (39-58):

1. **Synthesis of 3-(dimethylamino)-1-phenylprop-2-en-1-ones:** The reaction of dimethylformamide dimethylacetal (DMFDMA) (0.01 mol) with substituted acetophenones (0.01 mol) were carried out under reflux for 1 h in the presence of dioxane afforded the 3-(dimethylamino)-1-phenylprop-2-en-1-ones.

2. **Synthesis of 2-thioxo-1,3-dihydropyrido[2,3-d]pyrimidin-4(1H)-one derivatives:** 3-(Dimethylamino)-1-phenylprop-2-en-1-ones (0.01 mol) was refluxed for 2 h with 6-amino-2-thioxo-2,3-dihydropyrimidin-4(1H)-one (0.01 mol) in dioxane (20 mL) to give 2-thioxo-1,3-dihydropyrido[2,3-d]pyrimidin-4(1H)-one derivatives.

3. **Synthesis of 1,6-diphenyl-10,10a-dihydropyrido[2,3-d]-1,2,4-triazolo[4,3-a]pyrimidin-5(1H)-one derivatives:** 2-Thioxo-1,3-dihydropyrido[2,3-d]pyrimidin-4(1H)-ones, hydrazonoyl chlorides (1.25 g, 0.005 mol) and triethylamine (0.7 mL, 0.005 mol) in the presence of chloroform (40 mL) was added. The reaction mixture was refluxed until the hydrazonoyl chlorides disappeared (4-6 h) as indicated by TLC analysis. The solvent was evaporated under reduced pressure and the residue was treated with methanol (10 mL) afforded the 1,6-diphenyl-10,10a-dihydropyrido[2,3-d]-1,2,4-triazolo[4,3-a]pyrimidin-5(1H)-one derivatives.

Similarly, adopting the above procedures twenty derivatives of titled compounds were prepared by using different acetophenones (as per derivative table on p. 45) and characterized accordingly. The characterization data of synthesized compounds are as follows;

A. **1,6-Diphenyl-10,10a-dihydropyrido[2,3-d]-1,2,4-triazolo[4,3-a] pyrimidin 5(1H)-one (39):** Yield: 2.65 g (65 %); mp: 281-82 \( \text{DMSO} \), Found: C \( 69.96 \% \), H(4.99 %) N(20.40 %) (O(4.66 %), Anal.: C \( 69.86 \% \), H(4.88 %) N(20.30 %) O(4.55 %).

B. **6-(2-Methylphenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d][1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (40):** Yield: 2.55 g (55 %); mp: 283-85 \( \text{DMSO} \), Found: C \( 70.57 \% \), H(5.36 %) N(19.59 %) O(4.48 %), Anal.: C \( 70.44 \% \), H(5.24 %) N(19.48 %) O(4.38 %).

C. **6-(2,6-Dimethylphenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d][1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (41):** Yield: 2.35 g (45 %); mp: 280-81 \( \text{DMSO} \), Found: C \( 71.14 \% \), H(5.70 %) N(18.55 %), O(4.31 %), Anal.: C \( 71.02 \% \), H(5.64 %) N(19.75 %), O(4.21 %).

D. **6-(2-Chlorophenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d][1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (42):** Yield: 2.66 g (77 %); mp: 289-92 \( \text{DMSO} \), Found: C \( 75.10 \% \), H(4.08 %), CI(9.38 %) N(16.75 %), O(4.23 %), Anal.: C \( 75.03 \% \), H(4.02 %), CI(9.35 %) N(16.65 %).

E. **6-(4-Chlorophenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d][1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (43):** Yield: 2.60 g (70 %); mp: 285-87 \( \text{DMSO} \), Found: C \( 63.58 \% \), H(4.27 %) CI(9.38 %) N(18.54 %), O(4.12 %), Anal.: C \( 63.46 \% \), H(4.14 %), CI(9.28 %) N(18.45 %), O(4.12 %).

F. **6-(2,4-Dichlorophenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d][1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (44):** Yield: 2.20 g (58 %); mp: 278-80 \( \text{DMSO} \), Found: C \( 58.27 \% \), H(3.67 %) CI(17.20 %) N(16.99 %), O(3.88 %), Anal.: C \( 58.17 \% \), H(3.54 %), CI(17.10 %) N(16.85 %), O(3.77 %).

G. **6-(4-Methoxyphenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d][1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (45):** Yield: 2.62 g

---

International Journal of Pharmaceutical Sciences and Research 3413

H. 6-(3-Hydroxyphenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d] [1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (46): Yield: 2.85 g (82 %); mp: 285-87 (DMSO); IR: 3382-3270 (C-N stretching of primary amine), 1125-1074 (C-N stretching of secondary amine), 3361-3240 (Ar-N-H stretching), 1650 (C=O stretching), 3107-3082 (secondary N-H stretching cm⁻¹), 1270-1250 cm⁻¹ (C-O stretching of phenolic group) ¹H-NMR: δ 8.9-9.6 (s, 1H, Ar-NH), 7.26-8.06 (m, 12H, Ar-H), 5.40-6.42 ( s, 2H, Ar-NH₂) ppm; EIMS (m/z) : 358.14 (M⁺, 100). Found: C₂₀H₁₅N₆O₂; C(66.84 %) H(4.77 %) N(19.49 %) O(8.90 %), Anal.: C(66.77 %) H(4.65 %) N(19.38 %) O(8.80 %)

I. 6-(3-Nitrophenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d] [1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (47): Yield: 2.65 g (72 %); mp: 281-83 (DMSO), Found: C₂₀H₁₄N₆O₃; C(61.85 %) H(4.15 %) N(21.69 %) O(12.36 %), Anal.: C(61.77 %) H(4.10 %) N(21.59 %) O(12.25 %)

J. 6-(3-Aminophenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d] [1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (48): Yield: 2.68 g (74 %); mp: 278-80 (DMSO), Found: C₂₀H₁₆N₆O ; C(67.02 %) H(5.06 %) N(23.45 %) O(4.46 %), Anal.: C(66.99 %) H(5.01 %) N(23.35 %) O(4.36 %)

K. 6-(2-Bromophenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d] [1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (49): Yield : 2.25 g (63 %); mp: 278-80 (DMSO), Found: C₂₀H₁₅BrN₅O ; C(75.10 %) H(4.08 %) N(16.75 %) O(4.46 %), Anal.: C(75.01 %) H(4.02 %) N(16.65 %) O(4.50 %)

L. 6-(3-Methylphenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d] [1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (50): Yield : 2.85 g (85 %); mp: 288-89 (DMSO), Found:

C₂₁H₁₇N₅O ; C(75.10 %) H(4.08 %) N(16.75 %) O(4.56 %), Anal.: C(75.02 %) H(4.01 %) N(16.65 %) O(4.50 %)

M. 6-(2,4-Dimethylphenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d] [1,2,4] triazolo[4,3-a]pyrimidin-5(1H)-one (51): Yield: 2.78 g (76 %); mp: 274-76 (DMSO), Found: C₂₂H₂₀N₅O ; C(75.10 %) H(4.08 %) N(16.75 %) O(4.46 %), Anal.: C(74.99 %) H(4.00 %) N(16.64 %) O(4.48 %)

N. 6-(3-Chlorophenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d] [1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (52): Yield: 2.45 g (65 %); mp: 284-86 (DMSO), Found: C₂₂H₁₄ClN₅O; C(75.10 %) H(4.08 %) Cl(9.38 %) N(16.75 %) O(3.13 %), Anal.: C(74.98 %) H(3.97 %) Cl(9.38 %) N(16.66 %) O(3.13 %)

O. 6-(5-Chlorophenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d] [1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (53): Yield: 2.10 g (61 %); mp: 268-69 (DMSO), Found: C₂₂H₁₄ClN₅O; C(75.10 %) H(4.08 %) N(16.75 %) Cl(9.38 %) O(3.13 %), Anal.: C(74.98 %) H(4.00 %) N(16.68 %) Cl(9.35 %) O(3.10 %)

P. 6-(2,6-Dichlorophenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d] [1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (54): Yield: 2.85 g (85 %); mp: 288-90 (DMSO), Found: C₂₀H₁₃N₅Cl₂O ; C(75.10 %) H(4.08 %) N(16.75 %) Cl(17.38 %) O(3.24 %), Anal.: C(75.00 %) H(4.01 %) N(16.58 %) Cl(17.40 %) O(3.26 %)

Q. 6-(2-Methoxyphenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d] [1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (55): Yield : 2.69 g (69 %); mp: 286-88 (DMSO), Found: C₂₁H₁₇N₅O₂ ; C(75.10 %) H(4.08 %) N(16.75 %), O (4.52 %), Anal.: C(75.02 %) H(4.03 %) N(16.69 %) O (4.50 %)

R. 6-(2-Hydroxyphenyl)-1-phenyl-10,10a-dihydro-pyrido[2,3-d] [1,2,4] triazolo[4,3-a] pyrimidin-5(1H)-one (56): Yield : 2.15 g (58 %); mp: 280-82 (DMSO), Found:
C₂₀H₁₅N₅O₉; C(75.10 %) H(4.08 %) N(16.75 %) O(3.42 %), Anal. : C(75.01 %) H(4.04 %) N(16.59 %) O(3.40 %)

S. 6-(2-Nitrophenyl)-1-phenyl-10a-
dihydro-pyrido[2,3-d] [1,2,4] triazolo[4,3-
a] pyrimidin-5(1H)-one (57): Yield: 2.60 g (71 %); mp: 278-79°(DMSO); IR: 3382-
3270 (C-N stretching of primary amine), 1125-1074 (C-N stretching of secondary amine), 3361-3240 (Ar-N-H stretching), 1425-1410 (C-NO₂ stretching), 1650 (C=O stretching), 3107-3082 (secondary N-H stretching) cm⁻¹, ¹H-NMR: δ 8.9-9.5 (s, 1H, Ar-NH), 7.26-8.06 (m, 12H, Ar-H), 5.40-
6.42 ( s, 2H, Ar-NH₂) ppm; EIMS (m/z ) :388.1 (M⁺, 100). Found: C₂₀H₁₅N₆O₅; C (75.10 %) H (4.08 %) N (16.75 %) O(9.13 %), Anal. : C (74.95 %) H (3.96 %) N (16.58 %) O(9.10 %)

T. 6-(2-Aminophenyl)-1-phenyl-10a-
dihydro-pyrido[2,3-d] [1,2,4] triazolo[4,3-
a] pyrimidin-5(1H)-one (58): Yield: 2.55 g (66 %); mp: 275-76°(DMSO), Found: C₂₀H₁₆N₆O₅; C(75.10 %) H(4.08 %) N(16.75 %) O(3.13 %), Anal.: C(74.97 %) H(3.99 %) N(16.60 %) O(3.15 %)

RESULT AND DISCUSSION

Pharmacological Studies:

Anticonvulsant activity: The compounds under scheme (39-58) were evaluated for their anticonvulsant activity against Maximum Electroshock (MES) induced seizures while the selected compounds were evaluated against subcutaneous pentylentetrazole (scPTZ) induced seizure model in mice. The minimal motor impairment was measured by the rotarod (neurotoxicity) test.

All the test compounds were administered intraperitoneally (ip) at various dose levels ranging from 20-1000 µmol/kg body weight and the median effective dose (ED₅₀, dose of the compounds required to assure anticonvulsant protection in 50 % of animals from hind limp tonic extension), median toxic dose (TD₅₀) and protection index (PI) values were determined.

The anticonvulsant activity was carried out on albino mice (20-25g) of either sex or male albino rats (100-150 g) as experimental animals. The animals were divided into two groups (control and test) and each experimental group consisted of six animals (N=6). The animals were housed under standard conditions and allowed free access to standard pellet diet and water (ab libitum). Phenytoin was used as standard drug. The test compounds and standard drug were suspended in methyl cellulose in water (0.5%).

1. Maximum Electroshock (MES) Test: The test compounds (39-58) were administered intraperitoneally (ip) at a dose of 20-1000 µmol / kg body weight. Maximum electroshock seizure were elicited using electroconvulsometer with a 60 cycle altering current of 50 mA for 0.25 sec via ear clip electrode as per the procedure described by Swinyard et. At 171 effects was assessed at 0.5 h after administration by recording the tonic extension of the hind limbs at different doses. The reduction in time or absence of hind limb tonic extension of seizure is defined as protection.

Median effective dose (ED₅₀) was calculated at the doses of test compounds until at least three points were established in the range of 10-90 % seizure protection or minimal observed neurotoxicity. The results are presented in Table 3 Subcutaneous pentylentetrazole (scPTZ) seizure threshold test. Further, the most active compounds were evaluated against scPTZ model in mice pentylentetrazole dissolved in saline solution was administered in the posterior midline of the mice and the onset and severity of convulsion was noted for the control group. The test group was administered with the selected compounds 30 min prior to the administration of PTZ and the anticonvulsant activity was detected in terms of ED₅₀ (i.e. dose of the compounds required to assure anticonvulsant protection in 50 % of animals from hind limb tonic extension (tonic phase) and is presented in Table 1.)
2. **Neurotoxicity screening:** The neurotoxicity of all the test compounds was evaluated using rotorod test. Mice were trained to balance on the rotating rod (3.2 cm diameter) that rotates at 6 rpm and was allowed three attempts to remain on the rotating rod for 20 sec. Trained animals were treated with test compounds at a dose of 20-1000 µmol/kg administered intraperitoneally. Neurotoxicity was determined by the inability of the animal to remain on the rod for 1 min. Each of the trained animals was tested in this manner at 30 min after the administration of drug. The results are represented as mean toxic dose TD$_{50}$ [i.e. dose eliciting minimal neurological toxicity in 50 % of animals as assessed by the rotorod test (locomotor deficit)], which are further used in the calculation of PI (TD$_{50}$/ED$_{50}$) Table 1.

### TABLE 1: ANTICONVULSANT ACTIVITY DATA OF SYNTHESIZED COMPOUNDS

<table>
<thead>
<tr>
<th>Compd. No.</th>
<th>Intraperitoneal administration to mice</th>
<th>PI$^d$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MES$^a$ scPTZ$^b$ NT$^c$</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>106 111 ND 265</td>
<td>1.49</td>
</tr>
<tr>
<td>40</td>
<td>667 ND 653</td>
<td>3.10</td>
</tr>
<tr>
<td>41</td>
<td>517 615 ND 125</td>
<td>1.78</td>
</tr>
<tr>
<td>42</td>
<td>335 ND 140</td>
<td>1.24</td>
</tr>
<tr>
<td>43</td>
<td>295 660 ND 156</td>
<td>1.12</td>
</tr>
<tr>
<td>44</td>
<td>181 ND 198</td>
<td>1.15</td>
</tr>
<tr>
<td>45</td>
<td>180 ND 134</td>
<td>1.40</td>
</tr>
<tr>
<td><strong>46</strong></td>
<td><strong>152</strong> <strong>550</strong> <strong>108</strong></td>
<td><strong>3.95</strong></td>
</tr>
<tr>
<td>47</td>
<td>271 ND 187</td>
<td>1.42</td>
</tr>
<tr>
<td>48</td>
<td>209 ND 168</td>
<td>1.24</td>
</tr>
<tr>
<td>49</td>
<td>271 ND 221</td>
<td>1.18</td>
</tr>
<tr>
<td>50</td>
<td>205 ND 203</td>
<td>1.19</td>
</tr>
<tr>
<td>51</td>
<td>225 ND 270</td>
<td>1.34</td>
</tr>
<tr>
<td>52</td>
<td>204 ND 276</td>
<td>2.82</td>
</tr>
<tr>
<td>53</td>
<td>322 715 ND 213</td>
<td>1.28</td>
</tr>
<tr>
<td>54</td>
<td>259 ND 225</td>
<td>1.79</td>
</tr>
<tr>
<td>55</td>
<td>320 ND 270</td>
<td>1.46</td>
</tr>
<tr>
<td>56</td>
<td>244 ND 158</td>
<td>1.20</td>
</tr>
<tr>
<td><strong>57</strong></td>
<td><strong>585</strong> <strong>425</strong> <strong>633</strong></td>
<td><strong>4.05</strong></td>
</tr>
<tr>
<td>58</td>
<td>259 ND 787</td>
<td>1.03</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>646 ND 732</td>
<td>4.28</td>
</tr>
</tbody>
</table>

$^a$All compounds were administered by ip injection at doses of 20-1000 µmol/kg and values were determined at t=30 min. MES indicates maximum electroshock test and the data are represented in terms of ED$_{50}$. $^b$Subcutaneous pentylenetetrazole test. $^c$Neurotoxicity screening using rotorod test and values are expressed in terms of TD$_{50}$. $^d$Protection index (Pl=TD$_{50}$/ED$_{50}$). $^e$ND: activity not determined. All the activity data reaches the statistical significance p<0.05 (One way ANOVA ; Dunnet’s test).

**FIG. 3: ANTICONVULSANT ACTIVITY OF SYNTHESIZED COMPOUNDS (39-58)**
CONCLUSION: The compounds (39-58) were obtained with a good yield Scheme. These compounds exhibited expected anticonvulsant activity comparable with Phenytoin. The results of anticonvulsant activity (in vivo) indicated that the compounds (46) and (57) possessed significant anticonvulsant activity. The presence of electron withdrawing groups on the aromatic ring, in general, decreases the potency of the compounds compared to compounds having electron-donating groups. This may be because of low lipophilicity which in turn may decrease the permeability across the biological membranes. Further, it has been found that the ED50 and TD50 values of test compounds increase significantly at t=4 h, compared to t=30 min, in contrast to the standard, indicating that the compounds were metabolized with time in the biological environment. This trend was found to be more pronounced in the compounds (42), (43), (44), (47), (48), (49), (52), (53), (54) and (57) (having electron withdrawing groups) as compared to compounds (40), (41), (50), (51) and (55) (having electron-donating groups).

ACKNOWLEDGEMENT: Authors are thankful to Principal, Sharad Pawar College of Pharmacy, Nagpur for providing necessary facilities for carrying out this research work successfully.

REFERENCES:


How to cite this article:
Kawade DP and Khedekar PB: Synthesis and anticonvulsant activity of some new 1,6- diphenyl-10,10a-dihydropyrido[2,3-d]-1,2,4-triazolo[4,3-alpyrimidin-5(1h)-one derivatives. Int J Pharm Sci Res 2014; 5(8): 3409-17. doi: 10.13040/IJPSR.0975-8232.5(8),3409-17

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to ANDROID OS based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)